clinical trial · NCT05950334
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Relapsed/Refractory B-Cell LymphomaFT522RituximabCyclophosphamideFludarabineBendamustine
brief summary
This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine the recommended phase 2 dose (RP2D) of FT522 in combination with rituximab; each objective will be assessed with or without conditioning chemotherapy.
started
Nov 16, 2023
primary completion
Jun 6, 2025
completion
Jun 30, 2025
last updated
Aug 22, 2025
official title
A Phase 1 Study of FT522 in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol